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A simple and sensitive extractive spectrophotometric method has been described for the determination of
buprenorphine either in raw material or in pharmaceutical formulations. The developed method is based on the
formation of a colored ion-pair complex (1 : 1 drug/dye) of buprenorphine and bromocresol green (BCG) in
buffer pH 3 and extracting in chloroform. The extracted complex shows absorbance maxima at 415 nm. Beer's
law is obeyed in the concentration range of 1.32-100.81 μg mL−1. The proposed method has been applied
successfully for the determination of drug in commercial sublingual tablets and injectable dosage form. No
significant interference was observed from the excipients commonly used as pharmaceutical aids with the assay
procedure.
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Introduction
Buprenorphine (BUP) is a potent semi-synthetic opiate
analgesic with a potency of 20-40 times higher than that of
morphine.
1
 As an analgesic, it has been used successfully by
intramuscular, intravenous or sublingual routes for the treat-
ment of moderate to severe pain as well as chronic pain.
2
Like other opiates it can be abused.
3
 It has been suspected in
the doping of racehorses.
4
 Therefore, the matrices in which
BUP could be determined are very different, especially in
pharmaceuticals and biological samples. 
The analysis of BUP in biological samples is abundantly
described in the literature. Chromatographic techniques have
been widely employed since they are powerful separation
techniques. These methods based on liquid chromatography
with UV,
5-7
 fluorescence,
8
 electrochemical
9
 and mass
spectrometric detection have been applied to the analysis of
BUP in plasma or serum, whole blood, urine, feces, cad-
averic tissues or hair.
10
 Gas chromatography (GC) associated
with mass,
11
 electron capture detector
12
 was also used to
determine low concentrations of BUP biological samples.
The immunoassay techniques such as fluoroimmunoassay
13
and radioimmunoassay
14
 have been developed for the deter-
mination of this drug in biological samples. TLC was used
for determination of BUP in urine
15
 and pharmaceutical
preparations.
16
Although many analytic methods were reported to analyze
BUP in biological fluids, none of these methods was suitable
for the routine analysis of BUP in pharmaceutical prepa-
ration. Extractive spectrophotometric procedures are popular
for their sensitivity in the assay of drugs and, therefore, ion-
pair extractive spectrophotometry has received considerable
attention for the quantitative determination of many pharma-
ceutical compounds,
17-20
 and different alkaloids.
21,22
We, therefore, developed a simple and rapid spectrophoto-
metric method with a one-step extraction procedure for
determination of BUP in pharmaceutical preparations. This
method has been successfully applied to formulation studies
of BUP. 
Experimental Section
Materials and Reagents. Buprenorphine HCl (BUP·HCl)
was obtained from Diosynth (Apeldoorn, The Netherlands).
All chemicals were of analytical reagent grade of Merck
(Germany) unless otherwise specified. Doubly distilled water
was used to prepare all solutions. Freshly prepared solutions
were always employed. USP standard buffer solution (pH =
3) was prepared by diluting 50 mL of 0.2 M potassium
hydrogen phthalate and 22.3 mL of 0.2 M HCl to 200 mL
with distilled water.
23 
Bromocresol green solution (BCG, 1 ×
10
−4
 M) was prepared in distilled water. Pharmaceutical
grade of sodium alginate (MW = 10000-60000), maize
starch (MW = 50000-160000) and cellulose (MW = 243000)
were kindly donated by Soha Pharmaceutical Co (Tehran,
Iran).
Tablets containing 0.4, 2 and 8 mg active material were
supplied from local stores. The inactive ingredient in injec-
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tion dosage form is glucose and in the tablets are lactose,
mannitol, maize starch, povidone K30, magnesium stearate,
citric acid and sodium citrate. 
Apparatus. A Shimadzu UV-160A, UV-VIS spectrophoto-
meter (Japan) with 1 cm quartz cells was used for all
absorbance measurements. The pH value of all buffers were
adjusted using a Metrohm 692 pH meter.
Standard Solution of the Drug. A stock standard solu-
tion of BUP·HCl (1 × 10−3 M) was prepared by dissolving
BUP·HCl in doubly distilled water. Working standard
solutions were then prepared by suitable dilution of the stock
standard solution with water.
Recommended Procedure. Into a series of 100 mL
separating funnels, 10 mL of buffer solution of pH 3.0 and
20 mL of BCG were placed. An appropriate volume of 10
4
M standard drug solution (0.25-20 mL) was added to each
funnel and mixed well. The funnels were shaken vigorously
with 2 × 5 mL chloroform for 2 min, and then allowed to
stand for clear separation of the two phases. The separated
organic phase was transferred to a 50 mL beaker, dried over
anhydrous sodium chloride, and transferred to a 10 mL
volumetric flask. Then the combined extract was made up to
the mark with chloroform and mixed well. The absorbance
of the organic phase was measured at 415 nm against a
reagent blank similarly prepared. The standard calibration
curve was prepared to calculate the amount of the analyte
drug in unknown samples.
Procedure for the Dosage Forms. Twenty tablets were
weighed and ground to a fine powder using a pestle and a
mortar. The average weight of a tablet was calculated. An
accurately weighed portion of the powder, equivalent to 4
mg of BUP·HCl, was transferred into a 100 mL volumetric
flask. The volume was made up to the mark with water,
shaken well, and filtered through an ordinary filter paper.
Convenient aliquots from this solution were taken for the
determination of BUP. 200 μL of BUP·HCl injection was
used for determination of BUP without any dilution. 
Results and Discussion
Spectral Characteristics. Absorption spectra of the
yellow color BUP-BCG ion-pair complex is shown in Figure
1 with a maximum absorbance (λ
max
) at 415 nm. The
colorless blanks have practically negligible absorbance. 
Reaction Mechanism. Anionic dyes such as BCG forms
ion-pair complex with the positively charged drugs. The
drug-dye stoichiometric ratios as calculated by the continu-
ous variation and mole-ratio methods are found to be 1 : 1.
Each drug-dye complex, with two oppositely charged ions,
behaves as a single unit held together by an electrostatic
force of attraction (Scheme 1).
Optimization of Variables and Method Development.
A number of preliminary experiments established optimum
conditions necessary for rapid and quantitative formation of
colored ion-pair complex to achieve the maximum stability
and sensitivity. Optimum condition was fixed by varying
one parameter at a time while keeping other parameters
constant and observing its effect on the absorbance at 415
nm.
Effect of pH. The influence of pH of buffer solution on
the development and stability of the color using different
buffer systems such as phthalate, potassium hydrogen phtha-
late, phosphate and acetate buffers were tested in this study.
Potassium hydrogen phthalate-HCl buffer was the buffer of
choice, which did not interfere and gave the highest
sensitivity for complex formation and extraction. Different
pH (1-6) was tested and the absorbance reading of the BUP-
BCG ion-pair was examined (Fig. 2). The maximum color
intensity was observed in the pH range of 2.5-3.5 (Fig. 2)
and therefore 10 mL of pH 3 buffer solution, where maxi-
mum absorbance were achieved, was used throughout the
experiment.
Selecting of the Extracting Solvents. The effect of the
Scheme 1. Structure of analyte and formed ion pairs.
Figure 1. Absorption spectra of BUP-BCG ion-pair complex ex-
tracted into chloroform: BUP = 60 µg mL
−1 
+ 20 mL of 10
−4
 M of
BCG + 10 mL of Potassium hydrogen phthalate-HCl buffer pH 3.
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extracting solvent on the ion-pair complex was examined.
Chloroform was preferred to other solvents (carbon tetra-
chloride, dichloromethane, and ether) because of its slightly
higher efficiency on color intensity, selective extraction of
the BUP-BCG complex from the aqueous phase and
obtained highest absorbance with chloroform.
Composition of Ion-pair Complexes. The composition
of the ion-pair complex was established by Job’s method of
continuous variations using variable dye and BUP·HCl
concentrations. The results indicated that 1 : 1 (drug : dye)
ion-pair is formed through the electrostatic attraction
between the positive protonated drug and the anion of dye
(Fig. 3). The extraction equilibrium can be represented as
follows:
BUP
+
(aq)
 + D
−
(aq)
  ↔  BUP+D−
(aq)
  ↔  BUP+D−
(org)
where BUP
+
 and D
−
 represent the protonated BUP·HCl and
the anion of the dye, respectively. The subscript (aq) and
(org) refer to the aqueous and organic phases. Also, the
mole-ratio method showed the formation of 1 : 2 ion-pair
(Fig. 4). Shape of the resulting curve indicate that the ion-
pairs are labile. Consequently, a large excess of reagent must
always be used to enhance the formation of the complex. A
volume of 20 mL of BCG solution (10
−4
 M) was found to be
optimal for complete complexation. 
Solution and Colored Complex Stability. The solution
stability of the BUP and its tablet solutions was monitored
by keeping the solutions at room temperature (25 ± 1
o
C)
under darkness for several days and then recording the
absorption spectra of the solutions and also by performing
TLC analysis. There was no change in the absorption spectra
and amount of reference and sample solutions for at least
seven days determined by proposed method. The colored ion-
pair complex was stable for at least 48 h at 25 °C (Fig. 5).
Analytical Data. Under the optimized experimental condi-
tion, calibration curve was constructed by plotting the
absorbance at λ
max
 against the concentration of BUP. Beer’s
law was obeyed in the concentration range 1.32-100.81
μg mL−1 with molar absorption coefficients of 1.65 × 104 L
mol
–1
 cm
−1
. Regression analysis of the Beer's law plots at
λ
max
 reveals a good correlation (R
2
 = 0.9995). The graph
show negligible intercept and were described by the regres-
sion equation, y = 0.0175C + 0.0376 (where y is the ab-
sorbance of 1 cm layer, 0.0175 is the slope, 0.0376 is the
intercept and C is the concentration of the measured solution
in μg mL−1) obtained by the least-squares method. The high
molar absorptivities of the resulting colored complexes
Figure 2. Effect of pH Potassium hydrogen phthalate-HCl buffer
solution on the absorbance of BUP (25 µg mL
−1
)-BCG (20 × 10−4
M) ion-pair complex.
Figure 3. Job’s method of continues variation plot for ion-pair
complex of BUP·HCl by BCG in chloroform at 415 nm.
Figure 4. The effect of BCG concentration on color intensity and
extraction efficacy of BUP-BCG ion-pair complex by Mole-ratio
method (BUP·HCl = 50 µg mL
–1
 and BCG 10
−4 
M).
Figure 5. Stability of color complex of BUP-BCG in chloroform at
different concentration of BUP·HCl (◆ 25 µg mL
−1
 and ● 50 µg
mL
−1
).
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indicate the high sensitivity of the methods.
Method Validation. Samples of pure BUP·HCl at four
different concentrations were prepared and tested using the
proposed procedures in five replicates. The complete set of
validation assays was performed. The results obtained are
given in Table 1. The accuracy of the method is indicated by
the good recovery (97.1-101.83%), and the precision is
supported by the low relative standard deviation < 3.6%. 
Tablets and Injection Analysis. The proposed method
was successfully applied to the determination of BUP in
commercial sublingual tablets and injection form. The appli-
cability of the proposed methods for the assay of BUP in
formulations was examined by analyzing various formu-
lations and the results are tabulated in Table 2. Five repli-
cates determinations were made and satisfactory results
were obtained for drug and were in a good agreement with
the label claims (Table 2). A USP non-aqueous titration
method was employed as a comparison to evaluate the
validity of the proposed method. The comparison was
performed between BUP–BCG ion-pair formation method
and reference method (Table 2) in pharmaceutical prepa-
rations. The results were compared by the Wilcoxon test and
there was no significant difference between the methods at P
< 0.05. The results were reproducible with low RSD values.
The average percent recoveries obtained were quantitative
(99.5-99.75%), indicating good accuracy of method. The
results of analysis of the commercial tablets and the recovery
study of drug suggested that there is no interference in the
analysis from the commonly used additives and excipients in
pharmaceutical dosage forms of buprenorphine such as
glucose, dextrose, lactose, mannitol, maize starch, povidone
K30, magnesium stearate, citric acid and sodium citrate,
sodium alginate, and cellulose (Table 3). 
The maximum color development of BUP-BCG ion-pair
complex formation completed immediately after all reagents
were added. No heating or standing was needed. The reliabi-
lity of the method was established by parallel determination
against the official USP method (non-aqueous titration).
23
The present method is not time-consuming procedure such
as the standard addition method and there is no need for any
expensive equipment. These methods do not involve proce-
dural steps; take more operator time and expertise like
HPLC and other methods. On the other hand, in terms of
simplicity rapidity, sensitivity and expense, the method could
be considered superior in comparison with the previously
reported methods, especially with those based on chromato-
graphy,
5-9
 and the official USP method.
23
 The proposed
methods are simple and rapid with reasonable precision and
accuracy when compared to other reported methods. The
wide applicability of the described procedure for routine
quality control is well established by the assay of BUP in
pure form, as well as in pharmaceutical preparations.
A significant advantage of the extractive spectrophoto-
metric method is that it can be applied for the determination
of individual compounds in a multi component mixture.
Unlike the gas chromatographic and HPLC procedures, the
instrument is simple and is not of high cost. The importance
lies in the chemical reactions upon which the procedures are
based rather than upon the sophistication of the instrument.
This aspect of spectrophotometric analysis is of major
interest in analytical pharmacy since it offers distinct possi-
bility in the assay of a particular component in complex
dosage formulations. The reagents utilized in the proposed
methods are cheaper, readily available and the procedures do
not involve any critical reaction conditions or tedious sample
preparation. The method is unaffected by slight variations in
experimental conditions such as pH, reagent concentration
or temperature. 
Conclusions
In the present study, the ion-pair formation method can be
easily applied to the determination of BUP in raw material
and in pharmaceutical dosage forms. The proposed method
is simple, rapid and has good sensitivity and accuracy to
permit determination of low concentration even down to
1.32 μg mL−1. The performance of the proposed method has
been compared with other existing methods. It has been
Table 1. Evaluation of accuracy and precision for the proposed
method
Amount taken
μg mL−1
Recovery
%
RSD
a
%
RE
%
3 101.83 1.25 +1.83
10 97.10 3.60 −2.90
50 99.50 0.97 −0.50
a
Average of five determinations
Table 2. Determination of BUP·HCl in pharmaceutical preparations
Drug trade 
name
Label claim 
(mg)
% Recovery of BUP ± % RSD
a
Proposed method Official method
b
 
Temgesic Tablet 0.4 0.39 ± 2.50 0.39 ± 2.11 
2 2.01 ± 2.61 1.98 ± 1.97
8 7.98 ± 0.39 8.02 ± 0.44
Temgesic Injection 0.3 0.31 ± 2.12 0.29 ± 2.39
a
Average of five determinations. 
b
Ref. 23 (Non-aqueous titration)
Table 3. Determination of BUP·HCl
a
 in presence of excipient
Material
Amount
(mg)
% Recovery 
BUP ± % RSD
b
Glucose 20 99.51 ± 3.22
Dextrose 20 98.93 ±1.24
Lactose 20 99.37 ± 1.33
Manitol 20 99.31 ± 2.31
Maize starch 20 101.00 ± 0.59
Povidone K30 20 98.33 ± 1.86
Magnesium stearate 10 99.40 ± 1.43
Citric acid and sodium citrate 10 96.88 ± 2.46
Sodium alginate 10 99.10 ± 1.05
Cellulose 10 99.30 ± 0.48
a
50 μg mL−1 of BUP·HCl taken. baverage of five determinations 
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found that the proposed method has the following advan-
tages: (i) more rapid and easy to perform analysis compared
to non-aqueous titration (the official USP method); (ii) low
cost compared to GC, HPLC and immunoassay techniques.
These advantages encouraged the application of the propos-
ed method in routine quality control of burenorphine in raw
material samples and pharmaceutical preparations in pharm-
aceutical laboratories.
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